Does the media refer more to PTGX or BIIB?

In the previous week, Biogen had 53 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 66 mentions for Biogen and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Biogen's score of 0.91 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 34 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or PTGX?

In the previous week, Alnylam Pharmaceuticals had 37 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 50 mentions for Alnylam Pharmaceuticals and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INCY or PTGX?

In the previous week, Incyte had 32 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 45 mentions for Incyte and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Incyte's score of 0.76 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 20 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PTGX or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Roivant Sciences' score of 1.16 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or BNTX?

In the previous week, Protagonist Therapeutics had 7 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 6 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.58 beat BioNTech's score of 0.86 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protagonist Therapeutics (PTGX) Competitors

$136.64 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$136.73 +0.09 (+0.07%)

As of 07/31/2026 07:34 PM Eastern

Compare

PTGX vs. BIIB, ALNY, INCY, ROIV, and BNTX

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Roivant Sciences (ROIV), and BioNTech (BNTX). These companies are all part of the "biotechnology" industry.

How does Protagonist Therapeutics compare to Biogen?

Protagonist Therapeutics (NASDAQ:PTGX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protagonist Therapeutics presently has a consensus target price of $123.00, suggesting a potential downside of 9.98%. Biogen has a consensus target price of $223.36, suggesting a potential upside of 10.06%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A
Biogen	$9.89B	3.03	$1.29B	$5.65	35.92

In the previous week, Biogen had 53 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 66 mentions for Biogen and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Biogen's score of 0.91 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biogen	34 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Protagonist Therapeutics' net margin of -154.88%. Biogen's return on equity of 11.18% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Biogen	8.32%	11.18%	6.88%

Protagonist Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Summary

Biogen beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Alnylam Pharmaceuticals presently has a consensus target price of $410.72, suggesting a potential upside of 99.84%. Protagonist Therapeutics has a consensus target price of $123.00, suggesting a potential downside of 9.98%. Given Alnylam Pharmaceuticals' higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Protagonist Therapeutics' net margin of -154.88%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 37 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 50 mentions for Alnylam Pharmaceuticals and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.40	$313.75M	$5.38	38.20
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A

Summary

Alnylam Pharmaceuticals beats Protagonist Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Incyte has a net margin of 27.71% compared to Protagonist Therapeutics' net margin of -154.88%. Incyte's return on equity of 29.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

In the previous week, Incyte had 32 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 45 mentions for Incyte and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Incyte's score of 0.76 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	20 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Incyte has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.16	$1.29B	$7.85	15.23
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A

Incyte currently has a consensus target price of $117.74, indicating a potential downside of 1.49%. Protagonist Therapeutics has a consensus target price of $123.00, indicating a potential downside of 9.98%. Given Incyte's higher probable upside, equities research analysts plainly believe Incyte is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Incyte beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A
Roivant Sciences	$8.26M	2,952.84	-$299.77M	-$0.60	N/A

Protagonist Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -3,629.19%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Protagonist Therapeutics currently has a consensus price target of $123.00, indicating a potential downside of 9.98%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 0.94%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Roivant Sciences had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Roivant Sciences' score of 1.16 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to BioNTech?

Protagonist Therapeutics (NASDAQ:PTGX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Protagonist Therapeutics presently has a consensus target price of $123.00, indicating a potential downside of 9.98%. BioNTech has a consensus target price of $129.13, indicating a potential upside of 42.55%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Protagonist Therapeutics had 7 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 6 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.58 beat BioNTech's score of 0.86 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Protagonist Therapeutics has higher earnings, but lower revenue than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A

Protagonist Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

Protagonist Therapeutics beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.79B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-75.49	7.38	282.27	24.66
Price / Sales	118.65	1,250.98	581.52	86.64
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	13.90	16.78	10.93	6.07
Net Income	-$130.15M	-$12.56M	$3.49B	$347.99M
7 Day Performance	0.80%	-1.82%	-0.64%	-0.42%
1 Month Performance	3.81%	-8.45%	-3.78%	-4.80%
1 Year Performance	153.84%	48.33%	61.99%	18.61%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.5455 of 5 stars	$136.64 flat	$123.00 -10.0%	+153.8%	$8.79B	$74.06M	N/A	120	Positive News Upcoming Earnings
BIIB Biogen	3.9504 of 5 stars	$202.95 -2.4%	$223.36 +10.1%	+53.8%	$30.72B	$9.89B	35.92	7,500	Trending News Earnings Report Analyst Downgrade Gap Up
ALNY Alnylam Pharmaceuticals	4.791 of 5 stars	$205.52 +0.0%	$410.72 +99.8%	-48.9%	$27.43B	$3.71B	38.20	2,770	Trending News Analyst Forecast High Trading Volume
INCY Incyte	2.8563 of 5 stars	$119.52 -2.8%	$117.74 -1.5%	+58.1%	$24.93B	$5.14B	15.23	2,844	Earnings Report Analyst Downgrade Gap Up
ROIV Roivant Sciences	1.5764 of 5 stars	$33.91 -1.8%	$33.59 -0.9%	+199.8%	$24.83B	$8.26M	N/A	860	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INCY, ROIV, and BNTX

How does Protagonist Therapeutics compare to Biogen?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Protagonist Therapeutics compare to Incyte?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INCY, ROIV, and BNTX

How does Protagonist Therapeutics compare to Biogen?

Do institutionals & insiders believe in PTGX or BIIB?

Do analysts recommend PTGX or BIIB?

Which has stronger valuation and earnings, PTGX or BIIB?

Does the media refer more to PTGX or BIIB?

Is PTGX or BIIB more profitable?

Which has more risk & volatility, PTGX or BIIB?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts rate ALNY or PTGX?

Which has more risk and volatility, ALNY or PTGX?

Is ALNY or PTGX more profitable?

Do insiders & institutionals hold more shares of ALNY or PTGX?

Does the media favor ALNY or PTGX?

Which has stronger earnings & valuation, ALNY or PTGX?

Summary

How does Protagonist Therapeutics compare to Incyte?

Is INCY or PTGX more profitable?

Which has more risk & volatility, INCY or PTGX?

Does the media favor INCY or PTGX?

Do insiders & institutionals believe in INCY or PTGX?

Which has higher earnings and valuation, INCY or PTGX?

Do analysts prefer INCY or PTGX?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Do institutionals and insiders have more ownership in PTGX or ROIV?

Which has preferable earnings & valuation, PTGX or ROIV?

Which has more risk and volatility, PTGX or ROIV?

Is PTGX or ROIV more profitable?

Do analysts recommend PTGX or ROIV?

Does the media refer more to PTGX or ROIV?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Do analysts rate PTGX or BNTX?

Does the media refer more to PTGX or BNTX?

Do insiders & institutionals believe in PTGX or BNTX?

Which has stronger earnings & valuation, PTGX or BNTX?

Which has more volatility and risk, PTGX or BNTX?

Is PTGX or BNTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools